Vivet Therapeutics
VTX-PID is a technology aimed to deplete Neutralizing Antibodies (NAbs) levels for a given AAV serotype, to a level allowing proper AAV transduction and therefore desired efficacy. VTX-PID is developed both for patients presenting NAbs because of a previous infection and therefore non eligible for gene therapy; and for patients in need of gene therapy re-administration in case of loss of efficacy. VTX-806 is an AAV-based gene therapy for Cerebrotendinous xanthomatosis (CTX).
Basic Information
- Category: Rare Diseases
- Founded: 2017
- Headquarters: Paris, France
- Website: vivet-therapeutics.com
Documented Facts
- Email: info@vivet-therapeutics.com (No linked source recorded for this statement.)
Evidence and Sources
- Vivet Therapeutics — Official Site (official)
- Vivet Therapeutics on linkedin (social)
Citation Guidance
Explore Rare Diseases profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Vivet Therapeutics.
- Canonical profile: https://brandsource.ai/brands/vivet-therapeutics
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/vivet-therapeutics/json-ld
- Citation profile API: https://brandsource.ai/api/brands/vivet-therapeutics/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (81/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2025-10-27T08:35:04.334Z
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
VTX-PID is a technology aimed to deplete Neutralizing Antibodies (NAbs) levels for a given AAV serotype, to a level allowing proper AAV transduction and therefore desired efficacy. VTX-PID is developed both for patients presenting NAbs because of a previous infection and therefore non eligible for gene therapy; and for patients in need of gene therapy re-administration in case of loss of efficacy. VTX-806 is an AAV-based gene therapy for Cerebrotendinous xanthomatosis (CTX).
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 supporting source linked.
- 1 structured fact available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.